Expert Financial Analysis and Reporting

On April 14th, Santarus announced that a Court has ruled that five patents covering Santarus’ ZEGERID® (omeprazole/sodium bicarbonate) prescription products are invalid due to obviousness. These patents were the subject of lawsuits brought by Santarus against Par Pharmaceutical, Inc. The case was heard in a five-day bench trial that concluded on July 17, 2009. Santarus […]

Par Pharmaceutical’s launched at risk a its generic version of Zegerid capsules, Santarus responded by launching its own authorized generic, restructured its sales force and ceased promotion of Zegerid prescription products. The Zegerid patent litigation is still ongoing as SNTS filed an appeal to the US Court of Appeals for the Federal Circuit in late […]

Santarus has just anounced that Par has filed a paragraph IV challenge to Zegerid’s patents. Depending on the outcome there are two broadly divergent scenarios. The critical issue is whether Par will be found to infringe the Zegerid patents. If the patents are upheld, it will be a dramatic positive giving the company exclusivity until […]

Management was quite optimistic about prospects for 2009 as both Zegerid and Glumetza are doing well. The company is looking for a 24% gain in product revenues. Summary of Key Points 1. The Santarus analyst meeting was very encouraging in regards to the new product outlook. 2. The company could end the year with $65 […]

Overview I recently met with Debbie Crawford, Chief Financial Officer, and Martha Hough, Head of Investor Relations. I continue to feel that the chips are falling into place to make this an exciting investment opportunity. In this meeting we focused on the key components of the Santarus story.   Investment Overview Santarus is moving close […]